ClinicalTrials.Veeva

Find clinical trials for Non-Small-Cell Lung Cancer in Aurora, CO

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Lung Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Colorectal Cancer
Triple Negative Breast Cancer

Non-Small-Cell Lung Cancer trials near Aurora, CO, USA:

Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02)

This study was designed to evaluate the safety and efficacy of trastuzumab deruxtecan in HER2-mutated metastatic non-small cell...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Trastuzumab deruxtecan

Phase 2

Daiichi Sankyo

Aurora, Colorado, United States and 47 other locations

type of side effects may occur with the drug treatment. It will also measure the levels of drug in the body and preliminarily assess its anti-cancer...

Enrolling
Non-Small Cell Lung Cancer
Drug: DZD9008

Phase 1, Phase 2

Dizal Pharma

Aurora, Colorado, United States and 62 other locations

over time. The third main question is to see if ELVN-002 works to shrink cancers that have HER2 genetic abnormalities, particularly non...

Enrolling
HER2 Mutant Non-small Cell Lung Cancer
HER2-positive Metastatic Breast Cancer
Drug: ELVN-002
Drug: Trastuzumab emtansine

Phase 1

Enliven Therapeutics

Aurora, Colorado, United States and 36 other locations

with stage I-IIIA Epithelial Growth Factor Receptor (EGFR) -mutant non-small cell lung cancer before sur ...

Active, not recruiting
Stage IA Non-Small Cell Lung Cancer
Stage IIIA Non-Small Cell Lung Cancer
Drug: Osimertinib
Procedure: Therapeutic Conventional Surgery

Phase 2

University of California San Francisco (UCSF)
University of California San Francisco (UCSF)

Aurora, Colorado, United States and 2 other locations

NSCLC comprises of approximately 84 percent (%) of all lung cancers and is often diagnosed at advanced stage due to poor prognosis....

Active, not recruiting
Lung Cancer, Non-Small Cell
Drug: Chemotherapy
Drug: Dostarlimab

Phase 2

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Lone Tree, Colorado, United States and 57 other locations

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...

Active, not recruiting
Non-Small Cell Lung Cancer Metastatic
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Drug: Patritumab Deruxtecan (Fixed dose)
Drug: Patritumab Deruxtecan (Up-Titration)

Phase 2

Daiichi Sankyo

Aurora, Colorado, United States and 122 other locations

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemothe...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Paclitaxel
Procedure: Surgery

Phase 3

AstraZeneca
AstraZeneca

Aurora, Colorado, United States and 230 other locations

This study is being done to determine the efficacy and safety of cofetuzumab pelidotin in the PTK7-expressing, recurrent non-small ...

Active, not recruiting
Non-small Cell Lung Cancer (NSCLC)
Cancer
Drug: Cofetuzumab Pelidotin

Phase 1

AbbVie
AbbVie

Aurora, Colorado, United States and 25 other locations

This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 (adagrasib) versus docetaxel in patients who have been previously...

Active, not recruiting
Advanced Non Small Cell Lung Cancer
Metastatic Non Small Cell Lung Cancer
Drug: Docetaxel
Drug: MRTX849

Phase 3

Mirati Therapeutics
Mirati Therapeutics

Lone Tree, Colorado, United States and 227 other locations

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Telisotuzumab vedotin

Phase 2

AbbVie
AbbVie

Aurora, Colorado, United States and 252 other locations

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems